Unaudited Standalone and consolidated financial results for the quarter and half year ended 30th September 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.7 pts more than Nifty Microcap 250 and 4.1 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board approved unaudited financial results for the quarter and half year ended 30 September 2025. On a consolidated basis, H1 FY26 revenue stood at Rs 8,458 lakhs against Rs 6.23 lakhs in H1 FY25, with profit after tax of Rs 631 lakhs compared to a loss of Rs 6.23 lakhs earlier. Standalone H1 FY26 revenue was Rs 135 lakhs with PAT of Rs 98 lakhs, versus a loss of Rs 6.23 lakhs in H1 FY25. The growth is largely driven by newly consolidated subsidiaries, notably Sky International Trading WLL (Bahrain), which contributed Rs 4,247 lakhs in revenue and Rs 306 lakhs in PAT for H1. The company completed a 1:1 bonus issue on 31 July 2025, doubling share capital to Rs 15,761 lakhs. Net cash from operating activities was a healthy Rs 617 lakhs for the consolidated entity.
This represents a dramatic turnaround driven mainly by newly acquired/added subsidiaries, with the company swinging from losses to strong profitability and positive operating cash flows. Investors should note the sharp YoY surge reflects a change in consolidation scope rather than purely organic growth, and should track sustainability of subsidiary-level performance.